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Abstract
Background: The hypoxia-inducible factor (HIF) transcription complex, which is activated by low
oxygen tension, controls a diverse range of cellular processes including angiogenesis and
erythropoiesis. Under normoxic conditions, the α subunit of HIF is rapidly degraded in a manner
dependent on hydroxylation of two conserved proline residues at positions 402 and 564 in HIF-1α
in the oxygen-dependent degradation (ODD) domain. This allows subsequent recognition by the
von Hippel-Lindau (VHL) tumor suppressor protein, which targets HIF for degradation by the
ubiquitin-proteasome pathway. Under hypoxic conditions, prolyl hydroxylation of HIF is inhibited,
allowing it to escape VHL-mediated degradation. The transcriptional regulation of the
erythropoietin gene by HIF raises the possibility that HIF may play a role in disorders of
erythropoiesis, such as idiopathic erythrocytosis (IE).
Results: Patients with IE were screened for changes in the HIF-1α coding sequence, and a change
in the ODD domain that converts Pro-582 to Ser was identified in several patients. This same
change, however, was also detected at a significant frequency, 0.073, in unaffected controls
compared to 0.109 in the IE patient group. In vitro hydroxylation assays examining this amino acid
change failed to reveal a discernible effect on HIF hydroxylation at Pro-564.
Conclusion: The Pro582Ser change represents a common polymorphism of HIF-1α that does not
impair HIF-1α prolyl hydroxylation. Although the Pro582Ser polymorphism is located in the ODD
domain of HIF-1α it does not diminish the association of HIF-1α with VHL. Thus, it is unlikely that
this polymorphism accounts for the erythrocytosis in the group of IE patients studied.
Background
Hypoxia-inducible factor (HIF) is the master regulator of
a wide range of cellular functions including glycolysis,
erythropoiesis and angiogenesis [1,2]. HIF is a dimeric
transcription complex composed of an α subunit (either
HIF-1α, HIF-2α, or HIF-3α) and a β subunit (also known
Published: 09 September 2003
Molecular Cancer 2003, 2:31
Received: 07 August 2003
Accepted: 09 September 2003
This article is available from: http://www.molecular-cancer.com/content/2/1/31
© 2003 Percy et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/31
Page 2 of 7
(page number not for citation purposes)
as ARNT), and it binds to target genes containing hypoxia
response elements (HRE) in mammalian cells [3,4]. There
is an expanding list of HIF target genes that are involved
in a diverse range of cellular processes that include angio-
genesis, cell survival and proliferation, energy and glucose
metabolism, apoptosis, and erythropoiesis [3].
Both subunits of HIF are constitutively expressed, but
under normoxic conditions, the α subunit of the complex
is also constitutively hydroxylated on two conserved pro-
line residues (Pro-402 and Pro-564 in the case of human
HIF-1α) [5–8]. This prolyl hydroxylation, catalyzed by a
family of intracellular prolyl hydroxylases designated
PHD/HPH [9,10], allows recognition of the α subunits by
the von Hippel-Lindau tumor suppressor protein (VHL)
[11], a component of an E3 ubiquitin ligase complex that
targets these subunits for degradation by the ubiquitin-
proteasome pathway [4,12]. This complex also includes
Elongin C, Elongin B, Cullin2, and Rbx1 [13]. Thus, under
normoxic conditions, HIF-1α (and the other α subunits)
is essentially undetectable. Under hypoxic conditions,
HIF-1α prolyl hydroxylation, which is dependent on
molecular oxygen, is inhibited, thereby allowing HIF-1α
to escape VHL-mediated degradation. This therefore pro-
vides a framework for understanding how oxygen tension
can be directly coupled to HIF activation.
Knowledge of the regulation of HIF has important impli-
cations for understanding, and potentially treating,
ischemic cardiac and cerebrovascular disease. Moreover,
HIF plays a critical role in cancer [14–16], as HIF-induced
angiogensis is instrumental in promoting cell growth in
solid tumors and metastasis [17]. Elevated HIF expression
occurs under pathophysiologic conditions such as in the
hypoxic cores of enlarging solid tumors. HIF levels can
also be augmented by cancer-inducing mutations in onco-
genes such as p53, Src, and most notably, VHL [12]. VHL
mutations occur in the context of the von Hippel-Lindau
syndrome, a tumor predisposition syndrome in which a
germline mutation is followed by somatic mutation of the
remaining allele, thereby allowing the development of the
classic triad of renal cell carcinoma, pheochomocytoma,
and hemangioblastoma, in conformance with Knudsen's
two hit hypothesis. Importantly, bi-allelic VHL mutations
also occur in the majority of sporadic clear cell carcinomas
of the kidney. Most, but not all, of these mutations impair
or abolish the capacity of VHL to serve as an E3 ubiquitin
ligase for HIF [18,19], consistent with the central impor-
tance of this pathway in the pathogenesis of these tumors.
The critical importance of HIF in the transcriptional regu-
lation of the erythropoietin (Epo) also raises the possibil-
ity of involvement of the HIF-VHL pathway in disorders of
erythropoiesis, such as primary erythrocytosis. This disor-
der is characterized by over production of red cells and
inappropriately normal or elevated Epo levels. Indeed, in
patients with autosomal recessive Chuvash polycythemia
[20–22], an Arg200Trp mutation of VHL impairs its abil-
ity to polyubiquitinate HIF [23], thereby providing an
explanation for elevated Epo levels. In the present studies,
we screened the HIF-1α gene for base changes in patients
with idiopathic erythrocytosis. Sequencing the VHL bind-
ing region of HIF-1α detected one patient who was
homozygous for a Pro582Ser polymorphism and an addi-
tional eight patients heterozygous for the same polymor-
phism. However, screening of a group of normal controls
detected the same Pro582Ser polymorphism, and func-
tional studies failed to reveal a defect in HIF-1α hydroxy-
lation. Collectively, these studies identify Pro582Ser as a
common polymorphism of HIF-1α that does not appear
to affect either HIF-1α hydroxylation or subsequent recog-
nition by VHL.
Results and Discussion
We sequenced exon 12 of HIF-1α from a group of 55
patients, all of whom had raised or inappropriately nor-
mal Epo levels. Sequencing of the Epo receptor (EpoR)
gene from these patients as previously described [24]
failed to reveal any mutations. With the exception noted
below, none of the patients displayed mutations in VHL
[22]. From this group, we detected a heterozygous C to T
transition at nucleotide 1744 of HIF-1α in 8 individuals
(compare Figure 1A with 1B). An additional individual
was homozygous for the same base change (Figure 1C),
and both his parents were heterozygous. This individual
was heterozygous for the Arg200Trp VHL mutation
(C598T) seen in Chuvash polycythemia, and clinical fea-
tures of this patient, D1, have been described in a previous
report [22]. The C1744T polymorphism in the HIF-1α
gene abolishes the restriction site for Tsp 45I enzyme (Fig-
ure 1D), and a group of 48 caucasian normal anonymised
controls showing an equal male/female distribution were
screened employing this diagnostic site. Seven were also
found to have lost this site (in 6 of these, the C1744T pol-
ymorphism was directly confirmed by sequencing), thus
giving a predicted frequency for this polymorphism of
0.073 in the normal group compared to 0.109 for the
erythrocytosis patients. Sequencing of exons 9 and 15 of
HIF-1α, which includes Pro402 and Asn803, failed to
detect any further base changes in this group of patients.
It might be noted that of nine patients that we previously
reported as having Chuvash polycythemia [22], three of
these were found to be heterozygous for the C1744T pol-
ymorphism in HIF-1α.
The C1744T polymorphism predicts an amino acid
change of proline to serine at codon 582 (Pro582Ser).
This residue is of potential interest because it is embedded
in a Phe-Asp-Gln-Leu-Ser-Pro motif (where Pro is Pro-
582), which bears homology to the Leu-Xaa-Xaa-Leu-Ala-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/31
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Pro motif (where Xaa is any amino acid and Pro is the
hydroxylacceptor proline) present at the previously iden-
tified sites of hydroxylation at Pro-402 and Pro-564. Of
relevance here is the fact that mutations can be tolerated
at all positions of this motif with the exception of the
hydroxylacceptor proline [25]; hence, it is conceivable
that the proline (582) itself may be a hydroxylation site. It
may also be noted that this proline is conserved in all
mammalian HIF-1α proteins for which sequence infor-
mation is available, but is not present in either HIF-2α or
HIF-3α, or in HIF-1α from Xenopus laevis [26].
Detection of C1744T polymorphism Figure 1
Detection of C1744T polymorphism. Sequencing of exon 12 of the HIF-1α detected a heterozygous base change of C to 
T at nucleotide 1744 in 8 patients (Figure 1B) when compared to the normal sequence (Figure 1A). One patient, D1, was 
homozygous for this base change (Figure 1C). The position of the mutation is indicated by an arrow. Bases are as follows: G = 
black; A = green; T = red; C = blue. The C1744T mutation destroys the restriction site for Tsp 45I enzyme and the normal 
exon 12 PCR product is restricted in the presence of this enzyme into 4 fragments of 213, 156, 139 and 92 bp; in the presence 
of the C1744T mutation the 156 and 139 bp fragments are replaced with one of 295 bp. (Figure 1D). M1: 100 bp DNA ladder; 
M2: 25 bp ladder; 1: C1744 control individual; 2: heterozygous individual for C1744T polymorphism; 3: individual D1 
homozygous for C1744T polymorphism.
1A
1B
1C
1D
  M1       M2       1        2        3
295 bp
156 bp
139 bp
92 bp
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To test the possibility that Pro-582 itself might be a site of
hydroxylation by PHD, we first prepared proteins corre-
sponding to HIF-1α (531–575) or HIF-1α (569–589)
fused to GST, and then immobilized these on GSH-agar-
ose. The bound protein was then treated with PHD2,
washed, and incubated with 35S-labelled VHL to assess the
extent of prolyl hydroxylation. As shown in Fig. 2A, under
conditions where PHD2 hydroxylates the HIF-1α (531–
575) peptide (lane 3), which contains the primary site of
hydroxylation (Pro-564), we found no evidence that it
hydroxylates the HIF-1α (569–589) peptide (lane 4), at
least in a manner which permits subsequent recognition
by VHL.
While Pro-582 may not itself be a site of prolyl hydroxyla-
tion, it is in the vicinity of Pro-564, which is the primary
site of prolyl hydroxylation in HIF-1α. Hence, the
Pro582Ser substitution might affect HIF-1α hydroxyla-
tion at Pro-564. To examine this, we incubated 35S-
labelled wild type or Pro582Ser GAL4-HIF-1α (531–652)
with PHD2. Hydroxylated substrate was then isolated by
incubation with VHL-elonginB-elongin C (VBC) followed
by immunoprecipitation of the latter [10,25]. As shown in
Fig. 2B, both wild type and Pro582Ser GAL4-HIF-1α
(531–652) are hydroxylated in a similar time-dependent
fashion by PHD2 (compare lanes 2–5 with lanes 7–10).
Thus, the Pro582Ser polymorphism does not adversely
affect the in vitro hydroxylation at Pro-564 by PHD. This
conclusion is consistent with binding studies that have
shown that the tight interaction of HIF-1α ODD peptides
containing Hyp-564 to VHL does not require this residue
[26,27]. It is also consistent with the structure of HIF-1α
(549–582) Pro564Hyp cocrystallized with VHL, in which
Pro-582, unlike Hyp-564, was not visualized [26].
Finally, it is possible that the Pro582Ser polymorphism in
HIF-1α might only manifest a functional change in the
context of other mutations, such as the Arg200Trp muta-
tion in the VHL protein. To test this, we hydroxylated WT
or Pro582Ser GST-HIF-1α (531–652) with PHD2 and
tested the hydroxylated protein for interaction with VHL
Arg200Trp. As shown in Fig. 2C, this mutant VHL binds to
hydroxylated forms of both WT and Pro582Ser GST-HIF-
1α (531–652) (lanes 3 and 4, respectively). Collectively,
these results provide evidence that the Pro582Ser poly-
morphism does not interfere with recognition by Hyp-
564 HIF-1α by either WT (Fig. 2B) or Arg200Trp (Fig. 2C)
VHL. The latter observation indicates that this polymor-
phism is unlikely to account for the erythrocytosis seen in
the patient mentioned above who was heterozygous for
the Arg200Trp mutation in VHL.
It has been recently reported that human hormone-refrac-
tory prostate cancers possess mutations in the ODD of
HIF-1α [28]. One mutation that was identified turned
Effects of the Pro582Ser polymorphism on HIF-1α  hydroxylation Figure 2
Effects of the Pro582Ser polymorphism on HIF-1α 
hydroxylation. (A) GST pulldown assay. 5 µg of recom-
binant (His)6FlagPHD2 were incubated with 3 µg of either 
GST, GST-HIF-1α (531–575), or GST-HIF-1α (569–589) pre-
bound to GSH agarose under hydroxylation conditions, as 
indicated. The resins were washed, and were subsequently 
incubated with 35S-labeled, in vitro translated HA-VHL. Bound 
VHL was eluted and then subjected to SDS-PAGE and auto-
radiography. The position of HA-VHL is indicated. "In" desig-
nates 10% of the input HA-VHL. One of two representative 
results is shown. (B) VBC pulldown assay. 35S labeled, in vitro 
translated wild type or Pro582Ser GAL4-HIF-1α (531–652) 
was incubated with 1 µg of (His)6-PHD2 for the indicated 
times. Hydroxylated reaction products were then isolated by 
first incubating with (His)6-Flag-VBC, and then by immuno-
precipitation with anti-Flag antibodies coupled to agarose. 
The immunoprecipitated reaction products were subjected 
to SDS-PAGE and autoradiography. "In" designates 10% of 
the substrate. One of three representative results is shown. 
(C) GST pulldown assay. 1.5 µg of recombinant (His)6PHD2 
was incubated with 5 µg of either GST, GST-HIF-1α (531–
652), or GST-HIF-1α (531–652) Pro582Ser prebound to 
GSH agarose under hydroxylation conditions, as indicated. 
The resins were washed, and were subsequently incubated 
with 35S-labeled, in vitro translated FlagVHL Arg200Trp. 
Bound VHL was eluted and then subjected to SDS-PAGE and 
autoradiography. The position of VHL Arg200Trp is indi-
cated. "In" designates 10% of the input VHL Arg200Trp. One 
of two representative results is shown.
A
In
+G S T
+ GST-HIF-1α (531-575)
+ GST-HIF-1α (569-589)
VHL
In 0 20 40 60 In 0 20 40 60 time (min)
WT P582S
GAL4-HIF-1α
B
(531-652)
C
In
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+ GST-HIF-1α (531-652)
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VHL R200W
P582S
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out, in fact, to be the Pro582Ser mutation examined here.
A second mutation was an Glu591Gly mutation. Neigh-
boring normal tissue possessed wild type HIF-1α
sequence [28]. A previous report also documented the
occurrence of the Pro582Ser polymorphism in both renal
cell carcinomas and normal tissue [29]. While we cannot
rule out the formal possibility that the Pro582Ser poly-
morphism observed in the current studies or the previous
report might affect HIF-1α transcriptional activity, or HIF-
1α stability in the context of the full length protein, the
results presented here indicate that it does not affect either
hydroxylation at Pro-564 or its subsequent recognition by
VHL.
Conclusions
The C1744T transition is present in patients with IE but is
also a common polymorphism which is predicted to
result in Pro582Ser change in the HIF-1α amino acid
sequence. While this residue resides in the ODD domain
of HIF-1α, in vitro studies fail to reveal any impairment in
hydroxylation or subsequent recognition by VHL. Hence,
we conclude that the erythrocytosis observed in the
patients of the present study is likely due to other
mechanisms.
Methods
Patients
Idiopathic erythrocytosis patients from the UK and Ire-
land with elevated hemoglobin (Hb) (greater than 18 g/
dL in males and 16.5 g/dL in females), raised packed cell
volume (PCV) (above 0.51 in males and 0.48 in females),
with no splenomegaly and the absence of known second-
ary causes were recruited to our registry. Approval was
obtained from Queen's University, Belfast, Research Eth-
ics Committee for these studies and the use of the ano-
nymised controls and informed consent was provided
according to the Declaration of Helsinki.
Sequencing exons 9, 12 and 15 of the HIF-1α gene
Genomic DNA was isolated from peripheral blood using
a Nucleon BACC 1 DNA extraction kit (Nucleon Bio-
sciences, Manchester, UK). PCR was performed in a 100
µL reaction containing 10 % DMSO, 1.5 mmol/L MgCl2,
200  µmol/L dNTP, 0.5 µmol/L each of forward and
reverse primer, 2.5 units of Thermo-Start DNA Polymer-
ase (ABgene, Epsom, Surrey, UK) and 100 ng genomic
DNA, in 1× Thermo-Start Standard Buffer provided by the
manufacturer. The following primer sets were used: HIF
EX9F 5'-AAATCTTGAAATGTTCCTGTCCA-3' and HIF
EX9R 5'-GGGGCAAAAATATTTAAGCAAA-3' for exon 9;
HIF EX12F 5'-TTGCTGAAGACACAGAAGCAA-3' and HIF
EX12R 5'-TTGACTCAAAGCGACAGATAACA-3' for exon
12; HIF EX15F 5'-CCTAACACATTGTGGGTGTTT-3' and
HIF EX15R 5'-AGAAAATGAGCTGTCTGTGATCC-3' for
exon 15. Amplification was performed with an initial heat
activation step of 15 min at 95°C followed by 35 cycles of
95°C for 1 min, 55°C for 1 min and 72°C for 1 min in
the GeneAmp PCR system 2700 (Applied Biosystems,
Warrington, UK). PCR products were purified using Con-
cert Rapid PCR Purification System (Life Technologies,
Paisley, UK) and were sequenced using ABI Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit Version
3 on ABI 3100 DNA Genetic Analyzer (Applied
Biosystems).
Mutation screen for C1744T base change
The C1744T polymorphism abolishes the restriction site
for Tsp 45I enzyme; thus, 16 µL of PCR-amplified exon 12
were digested with 10 U of Tsp 45I (New England Biolabs,
Hitchin, UK) for 2 hours at 37°C and examined by agar-
ose electrophoresis.
Plasmids
pcDNA3-GAL4-HIF-1α (531–652) Pro582Ser was pre-
pared by QuikChange mutagenesis using pcDNA3-GAL4-
HIF-1α (531–652) [25] as a template and the following
two oligonucleotides: 5'-CCTTCGATCAGTTGTCAAGCT-
TAGAAAGCAGTTCCGC-3' and 5'-GCGGAACTGCTT-
TCTAAGCTTGACAACTGATCGAAGG-3'. pGEX-HIF-1α
(569–589) was constructed by subcloning into the BamH
I/Xho I site of pGEX-5X-1 a duplex comprised of the fol-
lowing two oligonucleotides:
5'-GATCCATGATGATGACTTCCAGTTAAGATCTTTCGAT-
CAGTTGTCACCATTAGAGAGCTCTTCCG-
CAAGCTAATCTAGAC-3' and
5'-TCGAGTCTAGATTAGCTTGCGGAAGAGCTCTCTAAT-
GGTGACAACTGATCGAAAGATCTTAACTGGAAGTCAT-
CATCATG-3'. pGEX-HIF-1α (531–652) was constructed
by standard recombinant DNA methods. pGEX-HIF-1α
(531–652) Pro582Ser was constructed by subcloning the
0.4 kb Eco RI/Spe I fragment of pcDNA3-GAL4-HIF-1α
(531–652) Pro582Ser into the Eco RI/Spe I site of pGEX-
HIF-1α (531–652). pcDNA3-FlagVHL Arg200Trp was pre-
pared by QuikChange mutagenesis using pcDNA3-
FlagVHL [30] as a template and the following two
oligonucleotides:
5'-CAAATGTGCAGAAAGACCTCGAGTGGCTGACACAG-
GAGCGC-3' and 5'-GCGCTCCTGTGTCAGCCACTCGAG-
GTCTTTCTGCACATTTG-3'.
Where appropriate, sequences of recombinant plasmids
were verified using a Big Dye Terminator kit and an ABI
automated sequencer. The sources of pGEX-HIF-1α (531–
575) and pcDNA3-HA-VHL have been described [25,30].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/31
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Proteins
(His)6PHD2, (His)6Flag-PHD2, and (His)6Flag-VBC were
purified from baculovirus-infected Sf9 cells as described
[25]. GST, GST-HIF-1α (531–575), GST-HIF-1α (569–
589), GST-HIF-1α (531–652), and GST-HIF-1α (531–
652) Pro582Ser were purified from E. coli transformed
with the appropriate plasmids by affinity chromatography
on GSH-agarose [31].
In vitro prolyl hydroxylation assays
GST pulldown assays
The assay was performed in two steps. First, GST, GST-
HIF-1α (531–575), GST-HIF-1α (569–589), GST-HIF-1α
(531–652), or GST-HIF-1α (531–652) Pro582Ser immo-
bilized on 10 µl of GSH-agarose was incubated with
recombinant PHD2 in 20 µl of buffer A (20 mM Hepes,
pH 7.9, 100 mM KCl, 1 mM DTT) supplemented with 100
µM FeCl2, 1 mM 2-oxoglutarate, 5 mM ascorbate, and 0.2
µg/µl bovine liver catalase (Sigma) for 1 hr at 30°C. The
resins were washed once with buffer A, and then incu-
bated with 5 µl of 35S-labelled, in vitro translated WT or
Arg200Trp VHL (prepared using pcDNA3-HA-VHL or
pcDNA3-FlagVHL Arg200Trp as templates, respectively,
and a TnTQuick T7 reticulocyte lysate kit) in 500 µl of
buffer A supplemented with 0.2% NP-40 and 0.2% BSA
with rocking for 1 hr at 4°C. The resins were washed three
times with buffer A supplemented with 0.2% NP-40,
eluted with 2× SDS-PAGE loading buffer followed by
heating at 100°C for 3 min, and the eluates then subjected
to SDS-PAGE and autoradiography.
VBC pulldown assays
VBC pulldown assays using (His)6PHD2 were performed
essentially as described [25], except that 1 mM DTT was
substituted for 1.4 mM β-mercaptoethanol and bovine
liver catalase was included in the hydroxylation reactions
at a final concentration of 0.3 µg/µl.
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